Europe Point-of-Care Testing (POCT) Market is Predicted to Observe Tremendous Growth: Achieving CAGR of 9.04% by 2032
As per the research report by Report Cube, the Europe Point-of-Care Testing (POCT) Market reached a value of nearly USD 8.52 billion in 2025. The market is expected to grow at a CAGR of around 9.04% during the forecast period of 2026-32, reaching a value of approximately USD 14.32 billion by 2032.
The increasing requirement for quick diagnostics that can provide convenient, accurate results beyond the conventional lab settings is further boosting the market demand. Further, the usage of point-of-care devices in hospitals, clinics, home care, and ambulatory settings in Europe has already increased, driven by the rising elderly population, growing burden of chronic & infectious diseases, and greater focus on early diagnosis.
Furthermore, the aftermath of COVID-19 was observed to have strongly emboldened public health infrastructure and prompted the implementation of portable diagnostic tools across the region. As healthcare systems pivot toward value-based care, point-of-care testing devices are proving instrumental in reducing turnaround times, improving clinical outcomes, and lowering overall treatment costs. This shift is further supported by technological innovations, such as miniaturized biosensors, connectivity integration, and multiplex testing platforms.
Also, as fast-track diagnostics continue to gain regulatory favor and EU-wide harmonization activities continue under IVDR (In Vitro Diagnostic Regulation), manufacturers are upscaling product pipelines and operations in line with the changing nature of the clinical requirements. Further, the proliferation of telemedicine and remote patient monitoring services has opened new avenues for POCT device deployment in rural and under-medicalized areas of Europe, further states the research study, the Europe Point-of-Care Testing (POCT) Market Analysis, 2026.
Analyzing the Europe Point-of-Care Testing (POCT) Market Segmentation
Hospitals Continue to Dominate the Europe Market
Based on End Users, the Europe Point-of-Care-Testing Market is segmented into Hospitals, Diagnostics Laboratories, Home Care Settings, and Others.
Among these, Hospitals are the leading sub-segment holding the highest market share, as hospitals are still the key end-users responsible for driving the Europe Point-of-Care Testing (POCT) Market. A rapid diagnostic tool capable of providing immediate results is urgently needed due to the high number of patients seen in emergency & intensive care departments. Additionally, adopting POCT devices to drive down diagnostic turnaround times, thereby making clinical decisions faster & accelerating time-critical diagnosis and treatment, for example, cardiac arrest, sepsis, and stroke.
Europe Point-of-Care Testing (POCT) Market Companies Analysis
With the strategic analysis & market study, the leading companies, including Menarini Industrie Farmaceutiche Riunite Srl, Abbott Laboratories, ACON Laboratories Inc., Becton Dickinson and Co., BioMerieux SA, Chembio Diagnostics Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Fluxerhy Inc., Johnson and Johnson Services Inc., and others, are predicted to contribute to the growing market outlook.
Key Questions Answered in the Research Report
- What is the predicted Europe Point-of-Care Testing (POCT) Market size and growth rate for the years 2026-32?
- What challenges are restricting the growth of the Europe Point-of-Care Testing (POCT) Market?
- What are the key Drivers, Trends, and opportunities defining the Europe Point-of-Care Testing (POCT) Market size?
- Which segment accounted for the largest market share in the Europe Point-of-Care Testing (POCT) Market?
- Which region has the maximum potential for the Europe Point-of-Care Testing (POCT) Market?
- Which prominent companies are leading growth in the Europe Point-of-Care Testing (POCT) Market?